Literature DB >> 12835571

Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides.

Reinhard Dummer1, Mirjana Urosevic, Werner Kempf, Dmitry Kazakov, Günter Burg.   

Abstract

Imiquimod is a topical immune response modifier that binds to Toll-like receptors 7 and 8 and induces alpha-interferon. We locally applied imiquimod 5% cream (Aldara) daily for 2 weeks on a PUVA- and retinoid-resistant plaque on the face of a patient with mycosis fungoides. The diagnosis was based on clinical appearance, histology and molecular studies. Most of the disease manifestations showed a clear remission during PUVA therapy combined with low-dose retinoids. However, the plaque on the face was PUVA resistant. Local imiquimod treatment resulted in the complete clearance of the plaque. The patient has now been in complete remission for 12 months. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12835571     DOI: 10.1159/000070962

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  13 in total

Review 1.  New targets of therapy in T-cell lymphomas.

Authors:  Jack Erter; Lapo Alinari; Kamruz Darabi; Metin Gurcan; Ramiro Garzon; Guido Marcucci; Mark A Bechtel; Henry Wong; Pierluigi Porcu
Journal:  Curr Drug Targets       Date:  2010-04       Impact factor: 3.465

Review 2.  Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome).

Authors:  Henry K Wong; Anjali Mishra; Timothy Hake; Pierluigi Porcu
Journal:  Br J Haematol       Date:  2011-08-25       Impact factor: 6.998

Review 3.  Immunopathogenesis and therapy of cutaneous T cell lymphoma.

Authors:  Ellen J Kim; Stephen Hess; Stephen K Richardson; Sara Newton; Louise C Showe; Bernice M Benoit; Ravi Ubriani; Carmela C Vittorio; Jacqueline M Junkins-Hopkins; Maria Wysocka; Alain H Rook
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

Review 4.  Therapeutic advances in cutaneous T-cell lymphoma.

Authors:  Oleg E Akilov; Larisa Geskin
Journal:  Skin Therapy Lett       Date:  2011-02

5.  Therapeutic Toll-like receptor agonists directly influence mouse and human T cell lymphoma cell viability and cytokine secretion.

Authors:  Angela Landrigan; Gloria Yiu; Kanika Agarwal; Paul J Utz
Journal:  Leuk Lymphoma       Date:  2011-09-13

Review 6.  Innovative therapy of cutaneous T-cell lymphoma: beyond psoralen and ultraviolet light and nitrogen mustard.

Authors:  Brian Poligone; Peter Heald
Journal:  Dermatol Clin       Date:  2010-07       Impact factor: 3.478

Review 7.  [Standard and experimental therapy of cutaneous T-cell lymphoma].

Authors:  M Beyeler; R Dummer
Journal:  Hautarzt       Date:  2003-12       Impact factor: 0.751

Review 8.  In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf.

Authors:  Linda Hammerich; Adam Binder; Joshua D Brody
Journal:  Mol Oncol       Date:  2015-11-10       Impact factor: 6.603

9.  Clearance of folliculotropic and tumor mycosis fungoides with topical 5% imiquimod.

Authors:  Matthew C Gordon; Jason C Sluzevich; Anokhi Jambusaria-Pahlajani
Journal:  JAAD Case Rep       Date:  2015-09-27

10.  Emerging treatment options for early mycosis fungoides.

Authors:  Montserrat Fernandez-Guarino
Journal:  Clin Cosmet Investig Dermatol       Date:  2013-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.